Reference analysis of one-year cost and patient payment of Lurbinectedin

Lurbinectedin (trade name: Zepzelca) is a new type of anti-tumor drug that blocks tumor proliferation by inhibiting the transcription and repair mechanisms of DNA in cancer cells. It is mainly used to treat patients with recurrence of small cell lung cancer (SCLC). Its indications are usually for patients who are no longer effective for first-line chemotherapy or other treatment options, providing new treatment options for clinical practice. Because it is an innovative drug, the cost of treatment is relatively high, and patients need to fully understand the financial burden and payment methods before taking the drug.

The original drug Rubicatin has been launched in China, but the specific price has not yet been announced. Therefore, domestic patients will not be able to obtain a clear annual treatment cost reference in the short term. If patients need to take medicine, they need to pay attention to the pricing and medical insurance reimbursement policies after the drug is launched. At the same time, combined with their own financial situation and treatment plan, they need to evaluate whether they can bear the cost of long-term treatment.

In overseas markets, the original drug Rubicatin is expensive. Taking the version sold in Hong Kong as an example, each box of 4mg sells for about 2 more than 10,000 yuan (the price is affected by exchange rate fluctuations). The price of the US original research version is about 90,000 yuan per box, and the Singapore version is about 3 more than 10,000 yuan per box. Since there are currently no generic drugs on the market overseas, patients need to bear all the drug costs themselves. Calculated on a one-year course of treatment, the financial burden is considerable.

When planning medication, patients should fully evaluate the cost of treatment, including drug costs, medical costs, and monitoring costs. Drugs can be obtained through legal overseas medical channels, and a reasonable course of treatment can be formulated under the guidance of a doctor. If the financial pressure is high, clinicians can evaluate the efficacy, consider staged treatment, or apply for a patient assistance program (PAP) to reduce the financial burden. On the premise of ensuring safety and efficacy, scientific arrangement of medication can maximize treatment benefits and reasonably control expenditures.

Reference materials:https://www.drugs.com/